|
|
Article: Expert: Sugen, Onyx Drugs Top Avastin In Renal Cancer.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Figuring out how well several developing drugs for renal cancer stack up against each other was one purpose of a conference call with two experts, hosted by SG Cowen & Co., of New York, but it turned out clear lines were hard to draw.
In the spotlight were three compounds. The first was BAY 43-9006, the vascular endothelial growth factor (VEGF) inhibitor and RAF kinase from Richmond, Calif.-based Onyx Pharmaceuticals Inc. and Bayer Pharmaceuticals Corp., a subsidiary of Bayer AG in Leverkusen, Germany. BAY 43-9006, granted fast-track status by the FDA, is in Phase III trials.
Another was SU011248, the multi-targeted tyrosine ...